Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Phio Pharmaceuticals Inc News

    0,70 $ +4,01% +0,027 $
    In : 0,6547 € | 15:38:37 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3D451
    ISIN: US71880W4024
    US-Symbol: PHIO
    Typ: Aktie

    Phio Pharmaceuticals Inc News

    06.12.23 - PR Newswire
    Thinking about buying stock in Brainstorm Cell Therapeutics, Clearmind Medicine, Phio Pharmaceuticals, Aspen Aerogels, or Immunoprecise Antibodies?
    Thinking about buying stock in Brainstorm Cell Therapeutics, Clearmind Medicine, Phio Pharmaceuticals, Aspen Aerogels, or Immunoprecise Antibodies? PR Newswire
    13.10.23 - PR Newswire
    Thinking about buying stock in T2 Biosystems, Lucid Group, Femasys, Groupon Inc, or Phio Pharmaceuticals?
    Thinking about buying stock in T2 Biosystems, Lucid Group, Femasys, Groupon Inc, or Phio Pharmaceuticals? PR Newswire
    02.06.23 - PR Newswire
    Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
    Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
    31.05.23 - PR Newswire
    Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
    Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
    24.05.23 - PR Newswire
    Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
    Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute ...
    18.05.23 - PR Newswire
    Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
    Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells PR Newswire
    16.05.23 - PR Newswire
    Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
    Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas PR Newswire
    11.05.23 - PR Newswire
    Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
    Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire
    20.04.23 - PR Newswire
    Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
    18.04.23 - PR Newswire
    Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
    18.04.23 - PR Newswire
    Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
    Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-​Enhanced in vivo Anti-​Tumor Efficacy of PD-1/CTLA-4 Dual-​Targeting INTASYL PR Newswire
    17.04.23 - PR Newswire
    Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
    Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-​Tumor Immunity PR Newswire
    22.03.23 - PR Newswire
    Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update
    Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update PR Newswire
    13.02.23 - PR Newswire
    Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
    Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements PR Newswire
    10.02.23 - PR Newswire
    Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
    Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification PR Newswire
    25.01.23 - PR Newswire
    Phio Pharmaceuticals Announces Reverse Stock Split
    Phio Pharmaceuticals Announces Reverse Stock Split PR Newswire
    06.01.23 - PR Newswire
    Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco
    Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco PR Newswire
    06.01.23 - PR Newswire
    Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors
    Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors PR Newswire
    21.12.22 - PR Newswire
    Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
    Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma PR Newswire
    10.11.22 - PR Newswire
    Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update
    Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update PR Newswire

    Newssuche

    Videos

    newspaper
    08:40 Uhr +7,82%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »